NCT01265199 - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Acute Myelogenous Leukemia (AML)

Interventions

DRUG

AT-406 in combination with daunorubicin and cytarabine

Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.

Trial Locations (6)

Unknown

Univerity of Chicago, Chicago

University of Michigan Health System, Ann Arbor

Washington University at St. Louis Siteman Cancer Center, St Louis

Memorial Sloan Kettering Cancer Center, New York

Hospital of the University of Pennsylvania, Philadelphia

Temple University at Jeanes Hospital, Philadelphia